ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 is a Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4.
Back to dashboard
Company Information
About this company
Key people
Zhengbin Yao
Chairman of the Board, President, Chief Executive Officer
Winston W. Kung
Chief Financial Officer, Treasurer
Robin LaChapelle
Chief Operating Officer
James Kastenmayer
General Counsel, Secretary
Kristine Peterson
Lead Independent Director
Stuart Lutzker
Director, President of Research and Development
James I. Healy
Independent Director
John A. Hohneker
Independent Director
Chris W. Nolet
Independent Director
Click to see more
Key facts
- Shares in issue49.31m
- EPICAVBP
- ISINUS04272N1028
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.44bn
- Employees77
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.